<DOC>
	<DOCNO>NCT01693029</DOCNO>
	<brief_summary>The purpose study show biosimilarity HX575 epoetin alfa US license reference product Epogen®/Procrit® apply subcutaneously . This study intend generate data support efficacy safety treatment HX575 Epogen®/Procrit® comparable .</brief_summary>
	<brief_title>Study Compare Safety Efficacy HX575 Epoetin Alfa US-licensed Epoetin Alfa</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients end stage renal disease ( stage CKD 5d ) , receive stable subcutaneous maintenance therapy Epogen® Procrit® least per week Mean hemoglobin level 9.0 11.5 g/dL screen period Adequate iron substitution Contraindications Erythropoiesis Stimulating Agent ( ESA ) therapy History Pure Red Cell Aplasia ( PRCA ) , antierythropoietin ( EPO ) antibodies Known Human Immunodeficiency Virus ( HIV ) Hepatitis B infection Hepatitis C infection active treatment Symptomatic congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) Unstable angina pectoris , cardiac infarction last 6 month prior randomization Percutaneous coronary intervention , coronary artery bypass graft last 6 month prior randomization History malignancy organ system Systemic lupus erythematous Immunocompromized patient Other In/Exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>erythropoietin alfa</keyword>
	<keyword>CKD 5d</keyword>
</DOC>